343 related articles for article (PubMed ID: 33609365)
1. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
[TBL] [Abstract][Full Text] [Related]
2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
3. Orexin OX
Jacobson LH; Chen S; Mir S; Hoyer D
Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
[TBL] [Abstract][Full Text] [Related]
4. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
[TBL] [Abstract][Full Text] [Related]
5. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
Mahoney CE; Mochizuki T; Scammell TE
Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
[TBL] [Abstract][Full Text] [Related]
6. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
8. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
[TBL] [Abstract][Full Text] [Related]
9. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.
Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M
Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823
[TBL] [Abstract][Full Text] [Related]
10. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
11. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.
Gotter AL; Forman MS; Harrell CM; Stevens J; Svetnik V; Yee KL; Li X; Roecker AJ; Fox SV; Tannenbaum PL; Garson SL; Lepeleire ID; Calder N; Rosen L; Struyk A; Coleman PJ; Herring WJ; Renger JJ; Winrow CJ
Sci Rep; 2016 Jun; 6():27147. PubMed ID: 27256922
[TBL] [Abstract][Full Text] [Related]
12. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.
Dugovic C; Shelton JE; Yun S; Bonaventure P; Shireman BT; Lovenberg TW
Front Neurosci; 2014; 8():28. PubMed ID: 24592208
[TBL] [Abstract][Full Text] [Related]
13. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
14. Investigation of New Orexin 2 Receptor Modulators Using
Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy.
Ito H; Fukatsu N; Rahaman SM; Mukai Y; Izawa S; Ono D; Kilduff TS; Yamanaka A
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2301951120. PubMed ID: 37796986
[TBL] [Abstract][Full Text] [Related]
16. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
17. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
[TBL] [Abstract][Full Text] [Related]
18. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice.
Etori K; Saito YC; Tsujino N; Sakurai T
Front Neurosci; 2014; 8():8. PubMed ID: 24550770
[TBL] [Abstract][Full Text] [Related]
19. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.
Black SW; Morairty SR; Fisher SP; Chen TM; Warrier DR; Kilduff TS
Sleep; 2013 Mar; 36(3):325-36. PubMed ID: 23449602
[TBL] [Abstract][Full Text] [Related]
20. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.
Black SW; Morairty SR; Chen TM; Leung AK; Wisor JP; Yamanaka A; Kilduff TS
J Neurosci; 2014 May; 34(19):6485-94. PubMed ID: 24806675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
